FDA approves low-cost HIV prevention shot
The FDA approved a cheaper version of a twice-yearly shot.
Why it matters: Lower prices may expand access.
Sources: AllAfrica · See it on the globe
One Turn
Open the globe →
The story so far · 3 days, November 2 to 4, 2026
FDA approves low-cost HIV prevention shot
One Turn followed this story across 3 editions, from Washington, D.C., United States on November 2, 2026. Newest first.
The shot needs two doses a year.
Open the latest on the 3D globe →
Day by day
- FDA approves first generic twice-yearly HIV prevention shot
- FDA approves generic twice-yearly HIV prevention shot
- FDA approves low-cost HIV prevention shot
Every installment
FDA approves generic twice-yearly HIV prevention shot
The FDA approved the first generic lenacapavir, a twice-yearly HIV prevention injection. It is expected to cost about $40 a year in 120 low- and middle-income countries.
Why it matters: Cheap access could greatly cut new HIV infections in poorer countries.
Sources: CBC News, AFP via France 24 via Wikipedia · See it on the globe
FDA approves first generic twice-yearly HIV prevention shot
The FDA approved a generic lenacapavir. It is expected to cost about $40 a year in 120 low- and middle-income countries.
Why it matters: Cheap prevention could cut HIV infections in poorer countries.
Sources: CBC News, AFP via France 24 via Wikipedia · See it on the globe